Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%.

Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the company’s collaboration with Pfizer, aiming to test Pfizer’s next-generation CDK4-selective drug atirmociclib in combination with Olema’s palazestrant, the research firm issued an ‘Outperform’ rating on the stock, along with a price target of $22.

This potential upside of over 130% is no accident, as many believe Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is strategically well-positioned with two key players in HR-positive breast cancer, with the company’s current palazestrant and ribociclib combination study with Novartis.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a California-based clinical-stage biopharmaceutical company developing and commercializing therapies for women’s cancers. Incorporated in 2006, the company is dedicated to impacting breast cancer.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.